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SUMMARY
Intravenous administration of 150-labeled
water and 6-[8F]-L-fluorodopa were used to
assess abnormal striatal activity in monkeys
after long.term recovery of unilateral lesions of
the dopaminergic nigro-striatal system induced
by the neurotoxin MPTP. PET data were
examined in relation to behavioral and
biological parameters. Cerebral blood flow and
6-[IF]-L-DOPA uptake were found to be
significantly reduced in the lesioned striatum,
compared to the unaffected side and to normal
controls. There was no correlation between
cerebral blood flow and any of the behavioral
parameters. The uptake rate constant of 18F-
DOPA from blood to striatum and the ratios of
striatum to occipital areas were highly
correlated to the concentrations of homovanillic
acid in the cerebrospinal fluid of the same
animals but not to the rotational behavior. This
MPTP-induced model of striatal dopamine
deficiency in primates presents similarities with
idiopathic Parkinson’s disease and may be used
to evaluate the effects of dopaminergic lesions
and transplants on brain function.
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INTRODUCTION
During the past decade, the neurotoxin 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP), which is relatively selective for the
dopaminergic (DA) nigro-striatal system, has
attracted increasing attention. While MPTP’s
neurotoxic properties were discovered in humans
/3,14/, it has been widely studied in other species.
In both human and non-human primates, MPTP
can produce a tangible and persistent parkinsonian-
like syndrome. This syndrome mimics some of the
clinical features of idiopathic Parkinson’s disease
(IPD), especially bradykinesia and rigidity.
Pharmacologic, neuropathologic and neurochem-
ical similarities also exist between IPD and the
MPTP-induced model. The neurotoxicity of MPTP,
however, has been shown to be dependant upon a
number of factors, including species, age, dose and
route of administration/15/.
In the rhesus monkey, systemic injections
produce a bilateral lesion of the nigro-striatal
system /2/. When MPTP is injected into one
internal carotid artery, the symptoms produced are
largely those of hemi-parkinsonism /2/. This
syndrome resembles the model induced by
injection of 6-hydroxydopamine (6-OHDA) in the
substantia nigra developed by Marshall and
Ungerstedt /17/ in the rodent. In the rodent, one can
make an in vivo assessment of the extent of the DA
lesion by the intensity of spontaneous turning
behavior, as well as the turning behavior induced
by the administration of substances that stimulate
the dopamine (DA) system such as apomorphine
and amphetamine.
In this study, using 6-[SF]fluoro-L-3,4-
dihydroxyphenylalanine (SF-DOPA) and xo-
labeled water with positron emission tomography
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(PET), we examined the pattern of distribution of
SF-DOPA and cerebral blood flow (CBF) in the
brains of rhesus monkeys after clinical recovery
from unilateral MPTP treatment and compared the
results with behavioral data. We discuss the model
of Parkinson’s disease induced by intra-arterial
injection ofMPTP in light of these data.
MATERIALSAND METHODS
Animal procedures
Eight naive male rhesus monkeys, rendered
hemi-parkinsonian by MPTP injections into the
internal carotid artery were used in this study. The
animals’ ages ranged from 3 to 14 years old (Table
1). The age was obtained either from birth records,
or from evaluation of the teeth and medical
histories.
MFrP infusions
The method of MPTP administration was
similar to that described by Bankiewicz et al. /1/
with the following modifications: Under sterile
conditions, the neck area above the right carotid
artery was incised and the artery isolated. All
branches except the internal carotid branch were
ligatod. MPTP (solubilized in 0.1 N HCL, 0.3 to
0.7 mg/kg in 20-30 ml heparizined Ringer’s
lactate) was then slowly infused over 20 min
through a sterile 22 tm Millipore filter and a 25-
gauge indwelling butterfly needle at a rate of 1-1.5
ml/min.
Generally, the-animal received an initial
infusion of 0.35 mg/kg of MPTP. This was
followed by an observation period of at least three
weeks in which hypokinesia and contralateral limb
movements were evaluated. The extent of
neurological impairment and the animal’s ability to
consistently display apomorphine-induced rotations
of at least 75 turns/h, determined whether another
MPTP infusion was given. Up to four MPTP
infusions were given, usually using a dose lower
than the initial dose. No animal was infused more
often than once every three weeks. The total
cumulative dose varied from 0.35 mg/kg to 1.5
mg/kg (Table 1).
Behavioral assessment
The neurological impairments observed after
acute MPTP treatment tended to regress with time;
however, after two or more MPTP treatments,
some mild contralateral impairments remained
after maximum recovery (5-6 months). This did not
significantly interfere with the animals’ ability to
eat, drink or groom. None of the unilateral MPTP-
treated animals in this study required L-DOPA
therapy. The animals were carefully observed in
their cages during the weeks preceding and
following the PET study and were rated for
hypokinesia, tremor, posture, vocalization and
feeding as normal, mildly, moderately or severely
impaired.
Following the last MPTP injection, rotational
behaviors of the animals were observed. The
animals were tested once per month, occasionally
twice per month, until a stable pattern of
contralateral rotation developed. The animals were
observed in their home cages by two investigators.
Following a 5 min observation period, during
which the number of spontaneous rotations was
recorded, the animals were injected with
apomorphine (0.15 mg/kg) in the gluteal muscle.
Three hundred and sixty degree rotations were
counted over a 60 min period. The investigators’
totals were averaged for each session. The direction
of the animals’ turns were recorded as either
ipsilateral (I) or contralateral (C) to the side of the
lesion. Table 1 depicts the mean rotations for each
animal during 3 sessions during the weeks
preceding and/or following the PET scan.
In addition, as described earlier /6/, CSF
samples were removed from the
cerebellomedullary cistern under aseptic conditions
and immediately frozen until assayed using
standard HPLC techniques /28/ for homovanillic
acid (HVA), 5-hydroxyindoleacetic acid (5)
and 3-methoxy-4-hydroxyphenylglycol (MHPG).
Assay results were averaged for each animal (Table
1).
PET studies
In the 8 to 14 months following the last MPTP
administration, when stable rotational behavior was
consistently observed, the animals received a PET
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scan examination using aF-DOPA to measure DA
function, and 50-labeled water to measure blood
flow. The preparation of the animal for the PET
study and scanner characteristics have been
described previously/6/.
Cerebral blood flow (CBF): 50-labeled water
studies
CBF studies using 50-labeled water (10-20
mCi) were performed before the :SF-DOPA studies
at 4 transaxial z levels. Data acquisition began
when radioactivity was registered in the brain. The
rapid reconstruction of the data insured accurate
verification of the position of the animal’s head in
the scanner. Blood sampling was usually not
performed for the CBF studies. Because the CBF
studies were performed immediately before the 3-4
h SF-DOPA studies with arterial sampling, we
wanted to reduce the amount of blood loss from
each animal in a given study. Moreover, it was very
unlikely that the absolute global or regional blood
flows could be meaningfully compared across
monkeys. Barbiturate administration and the depth
of anesthesia are known to affect global and
regional CBF results significantly and increase
their variability. Furthermore, although the original
barbiturate dose was the same in all animals,
additional low doses were given as needed through-
out the course of the study. Thus, there was likely
to be significant variability in pCO2 as well as other
parameters important for the valid calculation of
absolute CBF across animals.
Since we compared primarily the CBF pattern
in the ipsi- and contralateral basal ganglia of the
hemi-parkinsonian animals, we only reconstructed
the first 50-60 sec of the data. During this period,
regional CBF is lin.early related to the amount of
radioactivity in each region/9,19/.
The data were stored in four sets of images
corresponding to the injections at the four scanning
levels. From the four sets of images, the slice
where the basal ganglia was best represented was
identified. In this slice, the striatum usually appears
as a crescent that includes the head of the caudate
nucleus and the dorsal part of the putamen (Fig. 1).
Circular regions of interest (ROI) (0.84 cm2) were
positioned around the left and right striata and
occipital cortices on the same slice. Activity in the
slice was determined by drawing a ROI around the
brain using an edge finder.
Only normalized values were considered in the
CBF analysis. In a preliminary report /7/, the
striatal data were normalized to the whole brain
average. However, a more extensive analysis of the
data showed that the amount of brain tissue
included in the calculation of the whole brain
average was variable depending on the number of
slices containing the brain in the set of images from
which the striatal slice was chosen. To homogenize
the amount of brain tissue used in the
normalization procedure, we decided to use only
the activity in the slice containing the striatal ROIs.
Regional data were normalized by dividing the
regional values by the slice global value. Only
normalized blood flow values were used for
statistical purposes.
18F-DOPA studies
18F-DOPA PET data acquisition and analysis
were performed as previously described /4,6/.
Kinetic and anatomical data were separated into
two sets and analyzed separately.
An ROI was placed on the unaffected striatum
and symmetrically relocated on the lesioned
striatum. ROIs were also positioned on several
posterior cortical areas and the temporalis muscles
surrounding the monkey’s head. For each ROI,
time activity curves (TACs) were constructed from
the kinetic data and the striatum/cortex ratio.
Regional XSF accumulation was normalized to the
amount of mCi injected per kg of body weight. The
activity in the left and right posterior cortical areas
and muscles was averaged. Repeated measures
ANOVA was used to compare the ipsi- and
contralateral TACs and the other groups.
For each animal, a representative mean
striatum/cortex ratio was obtained by averaging the
values obtained between 120 and 180 min. The
position of putamen and caudate nucleus ROIs was
determined using previously described criteria/6/.
Ratios of 18F accumulation values in putamen and
caudate nucleus to a corresponding cortical area
were interpolated at 120 min.
Plasma and metabolite analyses were performed
as described in detail elsewhere /20/. Because of
technical difficulties, the metabolic profile was
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Fig. 1: Representative pictures of 18F-DOPA (bottom) and 1SO-labeled water (top) studies obtained in a unilaterally MPTP-
treated rhesus monkey. Each image is color coded on its own scale.
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obtained in only 5 of the hemi-parkinsonian
animals. A method derived from Patlak et al.
/25,26/and Martin et al./18/was used to perform a
graphical analysis of the aF-DOPA data for these 5
animals. Because of the very small and, therefore,
difficult to quantify accurately, amount (<2%) of
aF-DOPA present in plasma after 90 rain, the
graphical analysis was restricted to the first 90 rain
after isotope injection.
Statistical analysis
Monoamine metabolite concentrations in the
cerebrospinal fluid (CSF) and PET data from 9
normal and 4 bilaterally MPTP-treated monkeys
are reported in parallel to provide the reader with a
basis for comparison with the data from the
unilaterally lesioned animals (see Tables 2-4). All
the values are reported as the average of the left
plus right sides. These data were also used for
statistical population comparisons. The bilaterally
lesioned animals were characterized as
neurologically normal, i.e., the home cage activity
and posture were normal, they exhibited no
hypokinesia or tremor and displayed normal
feeding and vocalization behaviors. All 4 animals
presented some cognitive impairments in the
performance of tasks involving the frontal-striatal
dopaminergic systems /4/. The normal and
bilaterally lesioned animals were age, size and sex
matched with the unilaterally MPTP-treated
animals. The PET and CSF data were acquired
during the same time frame, using the same
procedures and analysis techniques as for the data
in the unilaterally injected monkeys. SF-DOPA
data, behavioral data and observations and MPTP
administration schedule are described in detail
elsewhere/4,6/.
For the PET studies in the unilaterally treated
monkeys, the ipsi- and contralateral sides were
compared using Student’s paired t-test. The
comparisons between the three groups were
performed by analysis of variance (ANOVA) with
Bonferroni correction for multiple comparisons.
The aF-DOPA time activity curves were compared
using repeated ANOVA. Left and right values were
averaged to determine the correlations between
CBF (normalized striatal CBF) and SF-DOPA data
(striatum/cortex ratios and uptake rate constants)
and behavioral parameters. Correlations were
analyzed using the least square analysis of the data.
For convenience, the aF-DOPA striatum/cortex
ratio is referred to as RA in the text, and all
regional CBF values refer to normalized regional
CBF values.
RESULTS
CSF catecholamine metabolites and behavioral data
in the hemi-parkinsonian monkeys
At the time of PET scannitg, monkeys M1 and
M2 showed no signs of impairment. Monkey M8,
the oldest animal, exhibited very moderate
hypokinesia in the contralateral side and reduced
activity in his home cage. When animals M3, M5
and M8 were at rest, their contralateral limbs
remained in a flexed, characteristic posture.
Monkeys M3, M4, M5, M6 and M7 preferentially
used their ipsilateral arm to obtain a presented treat
but readily used the contralateral arm as well when
presented with multiple treats at the same time. The
hypokinesia in the contralateral side was very mild.
None of the MPTP-treated animals had resting
tremor.
As expected, the unilaterally MPTP-treated
monkeys spontaneously turned ipsilaterally to the
side of the lesion. When challenged with
apomorphine, they turned to the side contralateral
to the lesion. No correlation was found between the
turning behavior, either spontaneous or under
apomorphine stimulation, and the CSF HVA,
5HIAA or MHPG, the striatum/cortex ratio, RA,
the uptake rate constant, K, or the CBF normalized
values.
CSF data for each of the hemi-parkinsonian
animals are summarized in Table 1. CSF HVA was
significantly lower in the hemi-lesioned monkeys
compared to normals (p<0.0001), but higher,
though non-significantly, than in the bilaterally
MPTP-treated monkeys. CSF 5HIAA in the MPTP-
treated animals was lower than in normals,
although the difference was not statistically
significant. CSF MHPG was similar in the three
groups. When the three groups were combined,
there was a significant correlation between the
striatum/cortex ratio RA (r--0.95, p<0.0001) and
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TABLE 2
Normalized regional blood flow values (mean _
SD) in normal controls, neurologically normal MPTP-treated monkeys
and the left (L) and right (R) side of the unilaterally MPTP-treated animals. The number in parentheses indicates the
number of subjects. The * indicates a significant difference (p<0.05) compared with controls (ANOVA).
Normal MPTP-treated L Hemi MPTP R Hemi MPTP
N--8 N=4 N=8 N=8
Striatum 1.070+0.083 1.123+0.048 1.148+0.054" 0.953+/-0.068*
Cortex 1. 261+/-0. 077 1. 280+1. 126 1. 328+0. 097 1. 290+0. 098
TABLE 3
Ratios striatum/cortex and rate constant for net uptake of lSF-DOPA from blood to striatum in normal, asymptomatic
MPTP-treated monkeys and the left and right side of the hemi-parkinsonian animals. The number in parentheses
indicates the number of subjects. The * indicates a significant difference compared with controls and the non-lesioned
side of the unilaterally MPTP-treated monkeys and the a significant difference with the asymptomati, bilaterally
MPTP-treated animals.
Normal
Caudate/- 2.634+/-0.16
cortex (N=9)
Putamen/- 2.508+/-0.103
cortex (N=9)
Striatum/- 2.752+/-0.29
cortex (N=9)
Uptake Rate 0.0146+/-0.0022
Constant (N=8)
MPTP-treated L Hemi MPTP R Hemi MPTP
1.84+/-0. 091* 2. 476+/-0.29 1.37+/-0. 113 *"
(N=4) (N=8) (N=8)
1.55+/-0. 081 * 2. 455+/-0. 338 i. 351+/-0.14 *"
(N--4) (N=8) (N=8)
1. 735+/-0. 099 * 2. 614+/-1. 435 1.48+/-0.118
(N=4) (N=8) (N=8)
0.0051+0.0011" 0.0135+/-0.0012
(N=3) (N--5)
0. 0047+/-0. 002*
(N=5)
TABLE 4
CSF content in HVA, 5HIAA and HHPG (in pmol/ml) of normal, neurologically normal MPTP-treated and hemi
MPTP-treated rhesus monkeys. The * indicates a significant difference from the normal control animals.
HVA (pmol/ml)
5HIA (pmol/ml)
MHPG (pmol/ml)
Normal
(N=9)
1332.8+222.4
330.6+56.7
85.7+12.6
MPTP-treated
(N=4)
544.4+/-70.8 *
285.2+/-29.8
76.1+7.87
Hemi MPTP
(N=8)
732.5+/-214.5"
271.9+/-90.7
91.8+/-27.8
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the rate constant K (r--0.91, p<0.001) with the CSF
HVA. There was a significant correlation between
RA, but not K, and the CSF 5HIAA (r--0.63,
p--0.002). There was no correlation between RA or
K and the CSF MHPG.
There was a negative correlation (r=-0.73,
p--0.04) between the age of the unilaterally
lesioned animals and RA. There was no correlation
with the dose of MPTP injected. However, because
MPTP effects are known to be age dependent, we
examined the strength of the correlation when age
and dose of MPTP were combined. Several
combinations of the two variables led to highly
significant correlations with RA. The most
significant were RAvs In(age + dose) (r=-0.86,
p--0.006) and RA vs In(age * dose) (r---0.78,
p--0.021).
150-labeled water studies
Data obtained in the hemi-parkinsonian animals
are summarized in Tables 1 and 2. There was a
statistically significant difference (p<0.0001)
between the left and right normalized blood flow
striatal values, while no significant difference was
apparent between the occipital areas (Fig. 1). The
striatal CBF of the MPTP-treated side in the hemi-
parkinsonian animals was significantly decreased
(p=0.0035) compared to the normal and
neurologically normal MPTP-treated monkeys.
Values from the "normal" non-treated side were
significantly increased (p=0.04) compared to
controls. Occipital CBF was similar in the normal
and all the MPTP-treated animals. There was no
significant correlation between the CBF data and
any of the behavioral parameters (age, dose of
MPTP, age-dose combination, spontaneous or
apomorphine-induced turning).
8F-DOPA studies
Data are summarized in Table 1. In the striatum
of the MPTP injected side, no 8F accumulation
was visually detectable in the entire striatum of 7 of
8 animals. A meager 8F striatal accumulation was
detectable in one slice of the youngest animal
(M1). Striatal aF activity was apparent in 4 to 5
slices of the anatomical set in the normal side of 7
of the 8 hemi-parkinsonian monkeys (Fig. 1). In the
oldest animal (M8), SF accumulation was apparent
in only 3 slices. The contrast between specific and
non-specific accumulation was also poorer in these
slices than in comparable slices obtained from the
younger animals. The loss of 8F accumulation
from the non-injected side was also indicated by its
lower RA value (Table 1).
There was a significantly lower 8F
accumulation in the MPTP-lesioned striatum of the
unilaterally treated animals compared to the non-
treated side, normal controls and asymptomatic
MPTP-treated monkeys (repeated measures
ANOVA). There was no significant difference in
striatal accumulation in the non-injected side
compared with normal controls. The lSF
accumulation in the posterior cortical areas and the
surrounding muscles was similar in both sides and
between the three groups.
As shown in Tables 1 and 3 and Fig. 2, the
striatum, putamen and caudate/cortex ratios on the
MPTP-injected side were significantly lower than
those of the non-treated side (p<0.01), and of
normal control and clinically normal MPTP-treated
animals (p<0.02). The striatum, putamen and
caudate nucleus/cortex ratios in the non-injected
side of the hemi-lesioned animals were not
significantly different from normal controls (Table
3).
The mean rate constant, K, for uptake of SF.
DOPA from blood into striatum was significantly
lower in the lesioned side of the unilaterally
MPTP-treated animals compared with the non-
injected side (p<0.0001) and normal control rhesus
(p<0.0001) (Table 3 and Fig. 3). K was similar in
normal monkeys and the intact side of the hemi-
parkinsonian animals.
There was no significant correlation between
the CBF data and RA and K in all groups.
DISCUSSION
18F.DOPA PET data
The SF-DOPA studies revealed a large
asymmetry in the striatum/cortex ratios and uptake
rate constant between the MPTP-injected and non-
injected sides of the hemi-parkinsonian animals.
Our study, performed 12-25 months after the last
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CONTROLS HEMI MPTP-TREATED TREATED
The ratios putamen/cortex (Put) and caudate
nucleus/cortex (CN) at 120 min after 18F-DOPA
injection. The filled triangles represent the values
for each animal. The bars indicate the mean for
each group. The * indicates a significant difference
between normal animals and the non-injected side
of the hemi-lesioned monkeys and the bilaterally
and unilaterally MPTP-lesioned animals (p<0.01).
The indicates a significant difference with the
bilaterally MPTP-treated animals. The [] indicates a
significant difference between the caudate and
putamen of the asymptomatic animals.
dose of MPTP, shows that the effects reported in
acute and sub-chronic studies/12,21/are likely to
remain even after the prolonged recovery period
that has been found by others/13/.
The striatum, eaudate and putamen/ortex ratios
of the MPTP-injeeted striatum are significantly
lower than those of the normal controls and
bilaterally MPTP-treated animals. In the bilaterally
MPTP-treated monkeys, the caudate nucleus
appeared less affected than the putamen (Fig. 2)
/6/, but the caudate and putamen were equally
affected in the hemi-parkinsonian preparation
(Table 3). The putamen receives projections from
the more ventral and posterior DA nigral neurons,
which are also the most sensitive to MPTP
neurotoxicity/11,29/. The more resistant caudate-
projecting neurons are increasingly affected with
exposure to MPTP. When the drug is infused
directly into the brain through the internal carotid
artery, the dose of MPTP in contact with DA
terminals is large and projections to both caudate
50
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Control K=0.016
Contra Hemi-HPTP K=0.0145
Ipst Hemi-HPTP K=0.0035
MPTP K=O,O06
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Fig. 3: Plots of the Patlak equation showing the
relationship between specific striatal radioactivity
(striatal activity minus reference area activity) and
integrated plasma 18F-DOPA activity during
steady-state (30-90 rain post injection). As
proposed by Martin et al. /18/, the slope of the
regression line equals the rate constant for net
uptake of 1SF-DOPA from blood to striatum, K
(ml/min/ml). Data are shown in three animals
representative of the three groups. For the normal
(*) and bilaterally MPTP-treated monkeys (0), left
and right data were averaged. Both lesioned (A) and
non-injected (t,) sides of the unilaterally lesioned
animal are shown.
nucleus and putamen are equally affected as
evidenced by the equally low caudate and
putamen/cortex ratios in the unilateral preparation.
The 8F-DOPA scans evaluated in this report
did not reveal a significant lesion of the
contralateral DA system (Table 1) in the animals as
a group. However, if monkeys M1 and M2, i.e., the
two animals devoid of manifest clinical symptoms,
except for spontaneous ipsilateral turning, were
excluded from the group, the striatum/cortex ratio
in the non MPTP-injected side (2.4 +/- 0.17) would
be significantly lower than in normal controls (2.75 __. 0.29) (19=0.02). Furthermore, we have recently
found evidence that this apparent normality may
result from the relative insensitivity of the standard
8F-DOPA scanning technique used (i.e. low signal
to noise ratio). Using a different, more sensitive
scanning technique, these same animals were found
to have reduced contralateral RA/5/. We believe
these more recent results reflect the likelihood that
MPTP is not completely trapped in the striatum
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during its first pass, that MPTP is not totally
metabolized by the liver before some of it is
reirculated, and that some cross perfusion between
the left and right arterial carotid system may occur.
8F-DOPA and biological parameters
CSF HVA, and to a lesser extent CSF 5HIAA,
and SF-DOPA PET data were strongly correlated.
CSF HVA has been shown roughly to reflect the
state of the DA system and DA activity in multiple
clinical studies. The slightly lower levels of5HIAA
in both groups of MPTP-treated animals suggests
that, at the dose used, MPTP may have induced
some subtle damage to the serotonin pathways. No
damage to the NE pathways is apparent from the
CSF levels of MHPG. It is noteworthy that in many
CSF studies in humans, changes in HVA and
5HIAA are closely paralleled while MHPG is not
/16/.
Neither spontaneous nor apomorphine-induced
turning behaviors correlate with the SF-DOPA
PET data, dose of MPTP administered, the
animal’s age, or the CSF HVA content. 8F-DOPA
is considered a good marker of dopaminergic
function, as is turning behavior in rodent students.
The lack of correlations between these two
parameters in our animals was surprising. It is
likely that multiple factors may account for the
discrepancy between the well established rodent
model and the non-human primate model. For
instance, MPTP’s effects are not limited to the
substantia nigra and DA systems/22/. The control
of turning behavior in the monkey may also differ
from the rodent.
Cerebral blood flow studies
The CBF in the lesioned striatum of the
unilaterally treated animals was significantly lower
than that in the non-injected side and the normal
controls. However, this decrease is unlikely to be
responsible for the concomitant decrease in SF-
DOPA striatal accumulation. For instance, the
bilaterally, neurologically normal MPTP-treated
animals who had no significant changes in striatal
CBF had a markedly decreased 8F-DOPA.
Similarly, the striatum contralateral to the MPTP
infusion presents an increase in blood flow with a
normal accumulation of SF. Furthermore, there
was no correlation between CBF and aF-DOPA
data in the three groups.
The CBF data in monkeys may help clarify
some of the CBF data reported in early and late
stages of IPD. Compared to normal striatal CBF,
the lesioned and unlesioned striata have,
respectively, significantly lower and higher CBF.
In human subjects, there is little agreement in the
literature on CBF in IDP. Some authors have found
increased striatal CBF in some patients/27/, others
found it decreased /30/ and some found it
unchanged/24/. Most of these differences could be
due to the clinical stage of the patients at the time
of the study. In humans, hemi-parkinsonism
appears to represent a very early stage of the
disease (Hoehn and Yahr I-II) with predominantly
unilateral symptoms. Usually, aF-DOPA PET
scans reveal that substantial amounts of aF-DOPA
uptake in the striatum (especially in the caudate
nucleus) contralateral to the affected limbs still
remains/10,23/. Classically, bilateral parkinsonian
patients are in later stages of the disease (Hoehn
and Yahr II-V) with pronounced impairment and
little or no SF-DOPA striatal accumulation,
especially in the putamen.
In the case of our MPTP-treated animals, the
bilateral, clinically normal MPTP-treated monkeys
and, perhaps, the non-injected side of the hemi-
parkinsonian animals may be considered very early
or sub-clinical cases of DA degeneration. In
contrast, the MPTP-injected side of the mild hemi-
parkinsonian animals, with little or no striatal 8F-
DOPA uptake left, may represent an example of
more advanced DA degeneration as seen in more
advanced stages of IPD. In this respect, our CBF
data are in good concordance with the patient data.
Roughly, CBF appears increased in the basal
ganglia in the very early stages (Hoehn and Yahr I-
II) of hemi-parkinsonism in patients/27,30/. In our
animals, in the slightly affected striatum, i.e. in the
asymptomatic bilateral rhesus or the striatum
contralateral to the MPTP infusion, CBF appears
higher than in normal controls, even though not
always significantly. This increase in striatal CBF
may represent a compensatory phenomenon, an
adaptation to limited nigro-striatal degeneration.
After a unilateral lesion, reorganization processes
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take place in both nigro-striatal systems and may
be mediated by increased synaptic DA activity in
the remaining neurons or by adaptative phenomena
in other neurotransmitter systems. It was
impossible to assess whether this apparent basal
ganglia increased CBF was the result of increased
CBF in the pallidum as suggested by Pdmutter
and Raichle/27/.
The significant decrease in striatal CBF
observed in the basal ganglia contralateral to the
mildly impaired limbs of the hemi-parkinsonian
animals parallels earlier reports showing reduced
striatal CBF in parkinsonian patients in advanced
stages of the disease /30/. Wolfson et al. /30/
suggested that this decreas in CBF could be
mediated by loss of DA innervation within the
blood vessels. There are few data on the effects of
MPTP on the blood-brain barrier and the DA
innervation of the arterial wall. However, it is
likely that the high doses of MPTP circulating
within the anterior cerebral artery affect DA
innervation in the vessels. Studies in cats and
humans showed that DA antagonists block
vasodilatation/8/. Drastic loss ofDA innervation in
the arteries may lead to decreased CBF through
increased vasoconstriction.
Alternatively, this striatal decrease may be due
to a generalized loss of function in the striatal
areas, involving non-DA neurons as well as DA
neurons, since the latter only represent 10% or less
of the population. We did not examine CBF in the
frontal cortical areas in our animals. The difficulty
in identifying this area accurately in our scanning
plane and the extensive partial voluming artifacts
we would have encountered, would have made the
frontal cortex determination subject to considerable
error. However, our behavioral studies suggest that
some frontal cortical functions in the MPTP-treated
animals are impaired. The combination of the loss
of DA innervation in the arterial wall and the
striatum and abnormal cortico-striatal and nigro-
striatal-induced functions may play a role in the
decrease in striatal CBF observed.
In conclusion, the model of dopamine
deficiency induced by unilateral infusion of MPTP
presents some, but not all, of the features of IDP. It
may be possible to mimic various stages of
impairment by careful gradation of the dose of
MPTP used in each single animal. This particular
model has already proven very helpful in the
development of transplantation techniques. The use
of XaF-DOPA and even CBF studies may be good
markers for the magnitude of the lesion and of the
success of the graft. However, turning behavior and
neurological observations of the animals may not
be the most effective methods to evaluate changes
in DA function, since, in the MPTP model, they
appear to have little correlation with the actual
amount of striatal DA after complete behavioral
recovery of the acute and sub-chronic effects of
MPTP.
Partial, preliminary data were reported in the
proceedings of the Symposium on Alzheimer’s and
Parkinson’s Disease: Basic and Therapeutic
Strategies, Kyoto, Japan, 1989/7/.
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